Jeffrey Nau - 01 Dec 2022 Form 4/A - Amendment Insider Report for Oyster Point Pharma, Inc.

Role
President and CEO, Director
Signature
/s/ Brandon Fenn, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Dec 2022
Net transactions value
-$100,106
Form type
4/A - Amendment
Filing time
06 Dec 2022, 18:05:49 UTC
Date Of Original Report
05 Dec 2022
Previous filing
08 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OYST Common Stock Tax liability $100,106 -8,938 -5.7% $11.20 148,660 01 Dec 2022 Direct F1
holding OYST Common Stock 1,000 01 Dec 2022 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units (the "RSUs"). Such RSUs were previously reported on the Reporting Person's Form 4 as to (i) 25,898 filed with the Securities and Exchange Commission on February 2, 2021 (the "2021 Award"); and (ii) 46,700 filed with the Securities and Exchange Commission on January 11, 2022 (the "2022 Award"). 6,474 RSUs of the 2021 Award and 11,675 RSUs of the 2022 Award were subsequently accelerated, effective December 1, 2022, resulting in the withholding being reported herein.
F2 These shares are held by the Reporting Person's spouse.

Remarks:

This amendment to Form 4 filed with the Securities and Exchange Commission on December 5, 2022 is being filed to correct the total number of shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in column 4 of Table I and adjust the total number of shares beneficially owned following the reported transaction in column 5 of Table I, accordingly.